Bundled-rate legislation for medicare reimbursement for dialysis services: Implications for anemia management with ESAs

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 12, 2010, Pages 2355-2362

  Charytan, Chaim ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRON;

ACT; AFRICAN AMERICAN; ANEMIA; COMPENSATION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIALYSIS; ERYTHROPOIESIS; HEALTH CARE COST; HEALTH SERVICE; HEMOLYSIS; HOME DIALYSIS; HUMAN; HYPOTONIC HYPORESPONSIVE EPISODE; MEDICARE; MEDICOLEGAL ASPECT; PATIENT CARE; REIMBURSEMENT; REVIEW;

ANEMIA; CONTINUITY OF PATIENT CARE; COST SAVINGS; HEALTH CARE COSTS; HEMATINICS; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; IRON; KIDNEY FAILURE, CHRONIC; MEDICARE; RENAL DIALYSIS; UNITED STATES;

EID: 78650386297     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04820610     Document Type: Review

References (66)

1. Pizzi LT: Economic considerations in a changing anemia environment. Am J Kidney Dis 52: S29-S33, 2008
2. Leavitt MO: Report to Congress. A design for a bundled end-stage renal disease prospective payment system. Available at: http://www.cms.hhs.gov/ ESRDGeneralInformation/Downloads/ESRDReportToCongress.pdf. Accessed June 3, 2009
3. Medicare program: End-stage renal disease prospective payment system. Final rule. Fed Regist 75: 49029-49214, 2010
4. Wish JB: The economic realities of erythropoiesis-stimulating agent therapy in kidney disease. Kidney Int 70[Suppl]: S21-S25, 2006
5. Thamer M, Zhang Y, Kaufman J, Cotter D, Dong F, Hernan MA: Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA 297: 1667-1674, 2007 (Pubitemid 46631625)
6. Medicare Improvements for Patients and Providers Act of 2008. Available at: http://www.asm.org/asm/files/cclibraryfiles/filename/000000004120/hr6331. pdf. Accessed June 3, 2009
7. GovTrack.us.H.R. 6331 - 110th Congress (2008). Available at: http://www.govtrack.us/congress/bill.xpd?bill=h110-6331. Accessed May 20, 2009
8. Centers for Medicare and Medicaid Services: Medicare coverage: End-stage renal disease prospective payment system. Available at: http://www.cms.hhs.gov/ default.asp? Accessed September 15, 2009
9. Medicare program: End-stage renal disease quality incentive program. Fed Regist 75: 49215-49232, 2010
10. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A, for the CREATE Investigators: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084, 2006
11. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, for the CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098, 2006
12. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361: 2019-2032, 2009
13. Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, Vaamonde CA, for the Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients: Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N Engl J Med 339: 578-583, 1998
14. Rossert J, Casadevall N, Eckardt KU: Anti-erythropoietin antibodies and pure red cell aplasia. J Am Soc Nephrol 15: 398-406, 2004 (Pubitemid 38140780)
15. Spinowitz B, Coyne DW, Lok CE, Fraticelli M, Azer M, Dalal S, Villa G, Rosansky S, Adamis H, Beyer U: C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. Am J Nephrol 28: 280-289, 2008
16. Bommer J, Asmus G, Wenning M, Bommer G: A comparison of haemoglobin levels and doses in haemodialysis patients treated with subcutaneous or intravenous darbepoetin alfa: A German prospective, randomized, multicentre study. Nephrol Dial Transplant 23: 4002-4008, 2008
17. Macdougall IC, Wiecek A, Leong R, Duliege AM, Lang W, Iwashita J, Chang S, Besarab A: Management of anaemia in chronic kidney disease with Hematide™, a novel synthetic peptide-based erythropoiesis stimulating agent. Presented at the 44th European Renal Association/European Dialysis and Transplant Association Congress; June 21 to 24, 2007; Barcelona, Spain
18. Coyne DW: A comprehensive vision for intravenous iron therapy. Am J Kidney Dis 52: S14-S20, 2008
19. Kapoian T: Challenge of effectively using erythropoiesis-stimulating agents and intravenous iron. Am J Kidney Dis 52: S21-S28, 2008
20. Kapoian T, O'Mara NB, Singh AK, Moran J, Rizkala AR, Geronemus R, Kopelman RC, Dahl NV, Coyne DW: Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 19: 372-379, 2008 (Pubitemid 351240658)
21. Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S, Zazra JJ, Anandan JV, Gupta A: Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 11: 530-538, 2000 (Pubitemid 30115083)
22. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR, the DRIVE Study Group: Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 18: 975-984, 2007 (Pubitemid 46434515)
23. Kovesdy CP, Kalantar-Zadeh K: Iron therapy in chronic kidney disease: Current controversies. J Renal Care 35[Suppl 2]: 14-24, 2009
24. Porter J: Pathophysiology of iron overload. Hematol Oncol Clin North Am 19[Suppl 1]: 7-12, 2005
25. Coyne DW, Auerbach M: Anemia management in chronic kidney disease: Intravenous iron steps forward. Am J Hematol 85: 311-312, 2010
26. Lu M, Cohen MH, Rieves D, Pazdur R: FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol 85: 315-319, 2010
27. Besarab A, Frinak S, Yee J: Initial dose conversion ratio of epoetin alfa to darbepoetin alfa does not predict future need for darbepoetin alfa in HD patients [SA-PO2407]. J Am Soc Nephrol 20: 662A, 2009
28. Johnson DW, Pollock CA, Macdougall IC: Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology 12: 321-330, 2007
29. Alter HJ, Klein HG: The hazards of blood transfusion in historical perspective. Blood 112: 2617-2626, 2008
30. Vella JP, O'Neill D, Atkins N, Donohoe JF, Walshe JJ: Sensitization to human leukocyte antigen before and after the introduction of erythropoietin. Nephrol Dial Transplant 13: 2027-2032, 1998 (Pubitemid 28356770)
31. Kalantar-Zadeh K, Lee GH, Miller JE, Streja E, Jing J, Robertson JA, Kovesdy CP: Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis 53: 823-834, 2009
32. Dunning S, Solid CA, Arneson T, Guo H, Gilbertson DT, Collins AJ: Dialysis facility-level racial variation and EPO costs: geographic representations [F-FC195]. J Am Soc Nephrol 20: 46A-47A, 2009
33. Himmelfarb J, Smedberg P, Hakim RM: Educational symposium: Impact of bundled payments on care for ESRD patients. Presented at the 2009 American Society of Nephrology Renal Week, San Diego, CA, October 27 to November 1, 2009
34. Roach JL, Wheeler J, Hirth R, Turenne M, Sleeman K, Chuang C, Messana J: Accounting for race and ethnicity in a dialysis prospective payment system [F-FC197]. J Am Soc Nephrol 20: 47A, 2009
35. Lee H, Manns B, Taub K, Ghali WA, Dean S, Johnson D, Donaldson C: Cost analysis of ongoing care of patients with end-stage renal disease: The impact of dialysis modality and dialysis access. Am J Kidney Dis 40: 611-622, 2002 (Pubitemid 34971291)
36. EPOGEN® (Epoetin Alfa) for Injection [Prescribing Information], Thousand Oaks, CA, Amgen, Inc., July 2008
37. Aranesp (Darbepoetin Alfa) for Injection [Prescribing Information], Thousand Oaks, CA, Amgen, Inc., July 2008
38. Roger SD: Extended administration of erythropoiesis-stimulating agents for optimising the management of renal anaemia: What is the evidence? Int J Clin Pract 62: 1413-1422, 2008
39. Council on Physician and Nurse Supply [Press Release]: CPNS Press Releases and News Coverage, 2009. Available at: www.physiciannursesupply.com/ news-press-releases.aspx. Accessed November 10, 2009
40. Trachsler J, Gluck Z, Dickenmann M, Gauthier T, Brunisholz M, Martin PY, Burnier M, Wahl C, Wuthrich RP: Parameters for successful monthly extended dosing of darbepoetin-alpha in patients undergoing hemodialysis. Clin Nephrol 71: 697-702, 2009
41. Jadoul M, Vanrenterghem Y, Foret M, Walker R, Gray SJ, on behalf of the Darbepoetin Alfa 20000144 Study Group: Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients. Nephrol Dial Transplant 19: 898-903, 2004
42. Klinger M, Arias M, Vargemezis V, Besarab A, Sulowicz W, Gerntholtz T, Ciechanowski K, Dougherty FC, Beyer U: Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: A randomized trial. Am J Kidney Dis 50: 989-1000, 2007 (Pubitemid 350122810)
43. Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U: Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2: 637-646, 2007
44. Levin NW, Fishbane S, Canedo FV, Zeig S, Nassar GM, Moran JE, Villa G, Beyer U, Oguey D: Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: A randomised non-inferiority trial (MAXIMA). Lancet 370: 1415-1421, 2007 (Pubitemid 47576167)
45. Canaud B, Mingardi G, Braun J, Aljama P, Kerr PG, Locatelli F, Villa G, Van Vlem B, McMahon AW, Kerloeguen C, Beyer U, on behalf of the STRIATA Study Investigators: Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: Results from STRIATA, a randomized phase III study. Nephrol Dial Transplant 23: 3654-3661, 2008
46. Carrera F, Lok CE, De FA, Locatelli F, Mann JF, Canaud B, Kerr PG, Macdougall IC, Besarab A, Villa G, Kazes I, Van VB, Jolly S, Beyer U, Dougherty FC: Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: A randomized comparative trial. Nephrol Dial Transplant [Epub ahead of print] doi: 10.1093/ndt/gfq305, 2010
47. Amgen Resolves EPO Patent Dispute with Roche [Press Release]. Thousand Oaks, CA, Amgen, Inc., December 22, 2009. Available at: http://www.amgen.com/ media/media-pr-detail.jsp?year=2009&releaseID=1368916. Accessed March 12, 2010
48. Affymax and Takeda Announce Phase 3 Trials Meet Primary Endpoints for Investigational Drug, Hematide™/Peginesatide, to Treat Anemia in Chronic Renal Failure with Some Differences Noted in Secondary Analyses [Press Release]. Palo Alto, CA, Affymax, Inc., June 21, 2010
49. Gurevich A, Yampolskiy A, Timokhovskaya G, Fenney L, Mayo M, Duliege AM: Interim analysis of once-monthly Hematide efficacy and safety in HD patients not on ESA treatment [F-PO1094]. J Am Soc Nephrol 20: 364A, 2009
50. Geronemus R, Kaplan M, Pergola P, Schiller B, Whittier F, Wright S, Zabaneh R, Zeig S, Duliege AM, Leong R, Besarab A, for the AFX01-09 Study Group: Interim evaluation of long-term safety and tolerability of Hematide™ during maintenance treatment of anemia in patients with CKD on hemodialysis [Abstract # 550961]. Am J Kidney Dis 51: B1-B27, 2008
51. Schiller B, Martin E, Pergola P, Zeig S, Whittier F, Covic A, Besarab A, Francisco C, Polu K, Duliege AM: Long-term clinical experience with Hematide™/Peginesatide in patients undergoing haemodialysis. Poster presented at XL-VII ERA-EDTA Congress, Munich, Germany, June 25-28, 2010
52. Woodburn KW, Fan Q, Winslow S, Chen MJ, Mortensen RB, Casadevall N, Stead RB, Schatz PJ: Hematide™ is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model. Exp Hematol 35: 1201-1208, 2007 (Pubitemid 47088782)
53. Macdougall IC, Rossert J, Casadevall N, Stead RB, Duliege AM, Froissart M, Eckardt KU: A peptide-based erythropoietin- receptor agonist for pure red-cell aplasia. N Engl J Med 361: 1848-1855, 2009
54. Schiller B, Doss S, De Cock E, Del Aguila MA, Nissenson AR: Costs of managing anemia with erythropoieses-stimulating agents during hemodialysis: A time and motion study. Hemodial Int 12: 441-449, 2008
55. Saueressig U, Kwan JTC, De Cock E, Sapede C: Healthcare resource utilization for anemia management: Current practice with erythropoiesis- stimulating agents and the impact of converting to once-monthly C.E.R.A. Blood Purif 26: 537-546, 2008
56. Bleyer AJ, Hylander B, Sudo H, Nomoto Y, de la Torre E, Chen RA, Burkart JM: An international study of patient compliance with hemodialysis. JAMA 281: 1211-1213, 1999 (Pubitemid 29163130)
57. Ifudu O, Chan E, Paul H, Mayers JD, Cohen LS, Brezsnyak WF, Herman AI, Avram MM, Friedman EA: Anemia severity and missed dialysis treatments in erythropoietintreated hemodialysis patients. ASAIO J 42: 146-149, 1996
58. Leggat JE Jr, Orzol SM, Hulbert-Shearon TE, Golper TA, Jones CA, Held PJ, Port FK: Noncompliance in hemodialysis: Predictors and survival analysis. Am J Kidney Dis 32: 139-145, 1998
59. Saran R, Bragg-Gresham JL, Rayner HC, Goodkin DA, Keen ML, Van Dijk PC, Kurokawa K, Piera L, Saito A, Fukuhara S, Young EW, Held PJ, Port FK: Nonadherence in hemodialysis: Associations with mortality, hospitalization, and practice patterns in the DOPPS. Kidney Int 64: 254-262, 2003
60. Wazny LD, Stojimirovic BB, Heidenheim P, Blake PG: Factors influencing erythropoietin compliance in peritoneal dialysis patients. Am J Kidney Dis 40: 623-628, 2002
61. Brophy DF, Daniel G, Gitlin M, Mayne TJ: Characterizing hospitalizations of end-stage renal disease patients on dialysis and inpatient utilization of erythropoiesis-stimulating agent therapy. Ann Pharmacother 44: 43-49, 2010
62. Spiegel DM, Gitlin M, Mayne T: Factors affecting anemia management in hemodialysis patients: A single-center experience. Hemodial Int 12: 336-341, 2008
63. Yaqub MS, Leiser J, Molitoris BA: Erythropoietin requirements increase following hospitalization in end-stage renal disease patients. Am J Nephrol 21: 390-396, 2001
64. Solid CA, Foley RN, Gilbertson DT, Collins AJ: Perihospitalization hemoglobin-epoetin associations in U.S. hemodialysis patients, 1998 to 2003. Hemodial Int 11: 442-447, 2007
65. McFarlane PA, Pisoni RL, Eichleay MA, Wald R, Port FK, Mendelssohn D: International trends in erythropoietin use and hemoglobin levels in hemodialysis patients. Kidney Int 78: 215-223, 2010
66. Locatelli F, Aljama P, Canaud B, Covic A, De FA, Macdougall IC, Wiecek A, Vanholder R: Target haemoglobin to aim for with erythropoiesis-stimulating agents: A position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp® Therapy (TREAT) Study. Nephrol Dial Transplant 25: 2846-2850, 2010